Proprietary Product Development

Arecor is committed to leveraging its ArestatTM platform to develop a portfolio of proprietary products enabling improved treatment for diabetes care via the innovative reformulations of approved proteins and peptides.

Technology Partnering

Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would simply not be possible using conventional formulation science.

  • PROPRIETARY DIABETES
    PRODUCT DEVELOPMENT
  • TECHNOLOGY
    PARTNERING

PROPRIETARY DIABETES
PRODUCT DEVELOPMENT

What is Diabetes?

Diabetes is a chronic condition that affects the body’s ability to control blood sugar level. If left untreated it can lead to serious health complications.

  • Ultra-Rapid Acting Insulin

    Significantly faster onset of action

    Improved glycemic control

    Desired advancement for artificial pancreas

  • Stable Aqueous Glucagon

    No stable aqueous glucagon currently available

    Ready to use pen to treat severe hypoglycemia

    Critical unmet need for bi-hormonal artificial pancreas

  • Ultra-Concentrated Rapid Acting Insulin

    Critical for miniaturisation of delivery devices

    Superior fast acting insulin for high dose users

TECHNOLOGY
PARTNERING

  • High concentration antibodies

    Most biotherapeutic products in development are monoclonal antibodies or related…

  • Lyophilised powder to liquid switch

    There is a clear need within the pharmaceutical industry to…

  • Intravenous to subcutaneous switch

    There are a broad range of biotherapeutic products both on…

  • Differentiated biosimilars with IP Protection

    The biosimilars market is a complex, highly competitive yet significant…

  • Superior peptides

    INSULINS & OTHER DIABETES PEPTIDES Arecor is leveraging its unique…

  • Thermostable therapeutics

    Most biotherapeutic products, particularly in liquid form, require refrigeration for…

Latest News and Events

  • 27th March 2019

    Arecor listed in Business Weekly’s ‘Killer50’

  • 20th March 2019

    ARECOR RECEIVES REGULATORY APPROVAL TO INITIATE PHASE I CLINICAL TRIAL FOR ULTRA-RAPID ACTING INSULIN PRODUCT

  • 11th March 2019

    PROACTIVEINVESTORS interview with CEO Sarah Howell re Arecor’s strengthening of its team with the appointment of an experienced Chief financial Officer

  • 7th - 10th January 2019

    JPMorgan 2019, San Francisco, 7-10 January 2019